- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04850638
Drug Interaction Between SHR4640 Tablets and Furosemide Tablets in Healthy Volunteers (Single Center, Single Arm, Open, Self-control)
July 7, 2022 updated by: Jiangsu HengRui Medicine Co., Ltd.
The purpose of this study was to evaluate the effect of SHR4640 tablets on the pharmacokinetics of furosemide tablets in healthy male volunteers, using a single-center, single-arm, open, self-control design.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
18
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- West China Hospital of Sichuan University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Voluntarily sign the informed consent form before the start of the activities related to this trial, and be able to understand the procedures and methods of this trial, and be willing to strictly abide by the clinical trial plan to complete this trial;
- Adult males aged between 18 and 45 (including both ends, whichever is the time of signing the informed consent form);
- Body weight ≥ 50kg and body mass index (BMI): 19~26kg/m2 (including both ends).
Exclusion Criteria:
- Have a fertility plan or refuse to use medically approved contraceptives within 1 month from the screening period to the last medication;
- Smokers (those who smoke more than 5 cigarettes per day on average);
- During the first month of screening, the average daily alcohol intake was more than 25g (for example, 750mL beer, 250mL wine, or 50mL liquor) or those who were positive for alcohol in blood test or alcohol breath test during screening;
- Those who have eaten grapefruit or its fruit juice products, any caffeine (such as coffee, tea, chocolate, cola or other caffeinated carbonated drinks, etc.), alcoholic food or beverages within 2 days before administration;
- Drug abusers or those who were positive in urine drug test during screening;
- The researchers judged that the subjects had medical conditions that affected the absorption, distribution, metabolism and excretion of drugs or reduced compliance
- Any clinical history of serious illness or any disease or condition that the researchers believe may affect the results of the trial, including, but not limited to, a history of circulatory, endocrine, nervous system, digestive, urinary or blood, immune, mental and metabolic diseases;
- Allergic constitution, or allergic to any ingredient in SHR4640 and furosemide tablets, or allergic to sulfonamides or thiazide diuretics, or allergic to any food ingredient, or having special dietary requirements, unable to follow a uniform diet;
- Previous history of urinary diseases (such as benign prostatic hyperplasia, urinary tract stenosis) or other diseases that lead to dysuria;
- Screen those who have undergone any operation within the first 3 months, or who have not recovered after the operation, or who may have a plan for operation or hospitalization during the trial;
- Those who donated blood (or lost blood) and donated blood (or lost blood) ≥ 400 mL within 3 months before screening, or received blood transfusion;
- During screening, physical examination, vital signs, laboratory examination (whole blood cell analysis, blood biochemical analysis, blood electrolyte examination, urine analysis, fasting blood lipids, thyroid function), 12-lead ECG, X-chest X-ray and abdominal B-ultrasound were abnormal and had clinical significance.
- When screening, systolic blood pressure was less than 90mmHg or greater than 140mmHg, and / or diastolic blood pressure was less than 60mmHg or greater than 90mmHg;
- Urinary system ultrasound suggested or suspected urinary system crystals or stones during screening;
- Those whose serum uric acid was higher than 420 μ mol / L or had a previous history of hyperuricemia and / or gout;
- The level of serum potassium was lower than that of 4.0mmol/L during screening.
- According to the serum creatinine within 2 weeks before administration, the glomerular filtration rate ((estimated glomerular filtration rate, eGFR) calculated by the simplified kidney disease diet adjustment (modification of diet in renal disease, MDRD) formula (Annex 1) is less than 90 mL/min/1.73 m ².
- Those who were positive for hepatitis B surface antigen (HBsAg), or anti-hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antibody, or syphilis antibody within one month before the screening;
- Screening people who have participated in any drug or medical device clinical trial within the previous 3 months (subject to signing informed consent);
- Used any prescription drugs, over-the-counter drugs, Chinese herbal medicines or dietary supplements within 2 weeks before screening.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SHR4640 tablets
|
SHR4640 tablets and furosemide tablets
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax
Time Frame: Day1 to Day10
|
Peak plasma concentration
|
Day1 to Day10
|
AUC0-t
Time Frame: Day1 to Day10
|
Area under the curve from the time of dosing.
Dosing time to the last measurable (positive) concentration.
|
Day1 to Day10
|
AUC0-inf (if available)
Time Frame: Day1 to Day10
|
Area under the curve from time 0 to infinity
|
Day1 to Day10
|
Ae
Time Frame: Day1 to Day10
|
Cumulative Amount of excretion
|
Day1 to Day10
|
CLr
Time Frame: Day1 to Day10
|
Renal Clearance
|
Day1 to Day10
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
t1/2
Time Frame: Day1 to Day10
|
Half time
|
Day1 to Day10
|
Tmax
Time Frame: Day1 to Day10
|
Time of maximum observed concentration.
|
Day1 to Day10
|
CL/F
Time Frame: Day1 to Day10
|
apparent clearance
|
Day1 to Day10
|
Vz/F
Time Frame: Day1 to Day10
|
apparent volume of distribution
|
Day1 to Day10
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 28, 2021
Primary Completion (Actual)
September 5, 2021
Study Completion (Actual)
September 14, 2021
Study Registration Dates
First Submitted
April 19, 2021
First Submitted That Met QC Criteria
April 19, 2021
First Posted (Actual)
April 20, 2021
Study Record Updates
Last Update Posted (Actual)
July 11, 2022
Last Update Submitted That Met QC Criteria
July 7, 2022
Last Verified
July 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHR4640-108
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Male Subjects
-
AkesoNot yet recruitingHealthy Male Subjects
-
Sunshine Lake Pharma Co., Ltd.Completed
-
RAPT Therapeutics, Inc.Completed
-
AstraZenecaParexelCompletedHealthy Male SubjectsUnited States
-
AstraZenecaParexelCompleted
-
Sunshine Lake Pharma Co., Ltd.Completed
-
Innovent Biologics (Suzhou) Co. Ltd.CompletedHealthy Male SubjectsChina
-
Shanghai Henlius BiotechCompletedHealthy Male SubjectsChina
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruiting
-
Vigonvita Life SciencesShanghai Institute of Materia Medica, Chinese Academy of SciencesCompleted
Clinical Trials on SHR4640 tablets and furosemide tablets
-
Centre of Clinical Pharmacology, Hanoi Medical...Not yet recruitingIrritable Bowel Syndrome With DiarrheaVietnam
-
Cara Therapeutics, Inc.RecruitingPruritus | Notalgia ParestheticaUnited States, Poland, Spain, Canada, Germany
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu vcare pharmaceutical technology co., LTDCompletedInflammatory Bowel DiseasesChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruiting
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingHematologic MalignancyChina
-
Jiangsu vcare pharmaceutical technology co., LTDRecruitingModerate to Severe Atopic DermatitisChina
-
Shenzhen NewDEL Biotech, Co., LtdShenzhen Innovation Center for Small Molecule Drug Discovery Co., Ltd.Enrolling by invitation
-
Akros Pharma Inc.CompletedSkin Diseases | Psoriasis | Plaque PsoriasisUnited States, Canada, Poland